Eli Lilly Signs $1.3 Billion AI Drug Discovery Deal with Superluminal
Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines valued at up to $1.3 billion to discover small-molecule …
All Posts
Schrödinger Ends CDC7 Inhibitor Program Following Two Patient Deaths in AML Trial
Schrödinger, founded in 1990 and known for its physics-based computational platform used in drug and materials discovery, has halted development …
Lantern Pharma Reports on Q2: Clinical Trials & New AI Prediction Tools
Dallas-based Lantern Pharma reported Q2 2025 results, marking progress across its oncology pipeline and AI drug development platform. The company …
FDA Grants De Novo Authorization to ArteraAI’s Multimodal AI Prostate Cancer Risk Software
The U.S. Food and Drug Administration has granted De Novo authorization to ArteraAI Prostate, a multimodal artificial intelligence (MMAI) software …
PolarisQB Launches Quantum-AI Drug Discovery Platform for Beta Testing
Polaris Quantum Biotech (PolarisQB) has launched QuADD (Quantum-Aided Drug Design), a SaaS platform combining quantum computing and AI for early-stage …
Gameto Gets $44M to Complete U.S. Phase 3 Trial of Stem Cell-Derived Ex Vivo Egg Maturation Therapy
Gameto has raised $44 million in a Series C round led by Overwater Ventures, bringing total funding to $127 million. …
Doximity Buys Pathway Medical for $63M, Expands AI Suite for Physicians
Doximity, a San Francisco based digital health company, has acquired Montreal-based Pathway Medical in a deal valued at up to …
Asimov to Apply AI-Driven CHO Expression Platform in BARDA-BioMaP Filovirus Antibody Manufacturing
Asimov will lead a project under the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority …
Tahoe Therapeutics Raises $30 Million to Expand Single-Cell Data Production for AI Models
Tahoe Therapeutics has raised $30 million in Series A financing, increasing total funding to $42 million and valuing the Palo …
Aging-Focused BioAge Posts Q2 2025 Results: Advances Metabolic Pipeline and Expands Longevity Data Platform
BioAge Labs reported second-quarter 2025 results alongside updates on its metabolic disease pipeline and human aging data platform. The company …
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies
Strand Therapeutics has closed a $153 million Series B financing led by Swedish investment firm Kinnevik, joined by Regeneron Ventures, …
From Data to Discovery: How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning
Scientific knowledge is expanding faster than at any point in human history, with PubMed indexing over 1.3 million new biomedical …